Skip to main content
Search

Pharmacogenetics of anxiolytics, stimulants and mood stabilisers

Published on January 28, 2026   24 min

A selection of talks on Clinical Practice

Please wait while the transcript is being prepared...
0:00
Hello. My name is Maria Jesús Arranz, and I am the head of the research laboratory and of the pharmacogenetics unit at Fundació Docència i Recerca Mútua Terrassa. I am a biologist by trade, and I have more than 30 years of experience in the pharmacogenetics of psychiatry. In this talk, I would like to describe the current knowledge on the pharmacogenetics of anxiolytics, stimulants, and mood stabilizers, and their clinical applications.
0:32
During the talk, after a brief introduction, we will revise the pharmacogenetic findings regarding anxiolytics, such as alprazolam and diazepam, stimulants such as amphetamines, and methylphenidates and mood stabilizers such as lithium and valproate. And we'll discuss the possible clinical applications of such findings.
0:56
We will start by discussing the pharmacogenetics of anxiolytics.
1:01
Mental disorders such as schizophrenia, bipolar disorder and depression are severe mental disorders relatively common in human populations, with a global prevalence higher than 10%. The first line of treatment for these disorders is the use of pharmacotherapy. Antipsychotics, antidepressants, anxiolytics, stimulants and mood stabilizers are the mainstay treatments for mental disorders. However, about 30 to 50% of patients do not respond to these treatments, and may also suffer severe side effects such as extrapyramidal side effects, weight gain, metabolic syndrome, sexual dysfunction, neutropoenias, etc. These side effects may be life-threatening and contribute to non-compliance.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Pharmacogenetics of anxiolytics, stimulants and mood stabilisers

Embed in course/own notes